These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22034456)

  • 1. Schizophrenia: vulnerability versus disease.
    Tsuang MT; Stone WS; Faraone SV
    Dialogues Clin Neurosci; 2000 Sep; 2(3):257-66. PubMed ID: 22034456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conceptualization of the liability for schizophrenia: clinical implications.
    Tsuang MT; Stone WS; Faraone SV
    Dialogues Clin Neurosci; 1999 Dec; 1(3):153-64. PubMed ID: 22034209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards the prevention of schizophrenia.
    Tsuang MT; Stone WS; Faraone SV
    Biol Psychiatry; 2000 Sep; 48(5):349-56. PubMed ID: 10978718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concurrent validation of schizotaxia: a pilot study.
    Stone WS; Faraone SV; Seidman LJ; Green AI; Wojcik JD; Tsuang MT
    Biol Psychiatry; 2001 Sep; 50(6):434-40. PubMed ID: 11566160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integration of schizophrenia with schizotypy: identification of schizotaxia and implications for research on treatment and prevention.
    Tsuang MT; Stone WS; Tarbox SI; Faraone SV
    Schizophr Res; 2002 Mar; 54(1-2):169-75. PubMed ID: 11853991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schizophrenia: family studies and treatment of spectrum disorders.
    Tsuang MT; Stone WS; Faraone SV
    Dialogues Clin Neurosci; 2000 Dec; 2(4):381-91. PubMed ID: 22033752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Schizotaxia": clinical implications and new directions for research.
    Faraone SV; Green AI; Seidman LJ; Tsuang MT
    Schizophr Bull; 2001; 27(1):1-18. PubMed ID: 11215539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of liability syndromes for schizophrenia: where did they come from and where are they going?
    Stone WS; Giuliano AJ
    Am J Med Genet B Neuropsychiatr Genet; 2013 Oct; 162B(7):687-97. PubMed ID: 24132901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Schizotaxia--theoretical construct or a tool for clinical research?].
    Parnowska D
    Psychiatr Pol; 2004; 38(5):783-94. PubMed ID: 15523926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurocognitive and clinical dysfunction in adult Chinese, nonpsychotic relatives of patients with schizophrenia: Findings from the Changsha study and evidence for schizotaxia.
    Stone WS; Hsi X; Tan L; Zhu S; Li L; Giuliano AJ; Seidman LJ; Tsuang MT
    Asian J Psychiatr; 2012 Mar; 5(1):83-92. PubMed ID: 22773937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding predisposition to schizophrenia: toward intervention and prevention.
    Tsuang MT; Stone WS; Faraone SV
    Can J Psychiatry; 2002 Aug; 47(6):518-26. PubMed ID: 12211879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of schizophrenia.
    Tsuang MT; Stone WS; Auster TL
    Expert Rev Neurother; 2010 Jul; 10(7):1165-74. PubMed ID: 20586696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genes, environment and schizophrenia.
    Tsuang MT; Stone WS; Faraone SV
    Br J Psychiatry Suppl; 2001 Apr; 40():s18-24. PubMed ID: 11315219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The schizophrenia prodrome revisited: a neurodevelopmental perspective.
    Cornblatt BA; Lencz T; Smith CW; Correll CU; Auther AM; Nakayama E
    Schizophr Bull; 2003; 29(4):633-51. PubMed ID: 14989404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions.
    Cannon TD; van Erp TG; Bearden CE; Loewy R; Thompson P; Toga AW; Huttunen MO; Keshavan MS; Seidman LJ; Tsuang MT
    Schizophr Bull; 2003; 29(4):653-69. PubMed ID: 14989405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward reformulating the diagnosis of schizophrenia.
    Tsuang MT; Stone WS; Faraone SV
    Am J Psychiatry; 2000 Jul; 157(7):1041-50. PubMed ID: 10873908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically?: Results from the Changsha study.
    Stone WS; Hsi X; Giuliano AJ; Tan L; Zhu S; Li L; Seidman LJ; Tsuang MT
    Asian J Psychiatr; 2012 Mar; 5(1):73-82. PubMed ID: 22489255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validating schizotaxia and its place in studies of preventing schizophrenia by psychopharmacological intervention.
    Tsuang MT; Stone WS; Tarbox SI; Faraone SV
    Essent Psychopharmacol; 2005; 6(2):91-103. PubMed ID: 15765793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The genetics of schizophrenia.
    Tsuang MT; Stone WS; Faraone SV
    Curr Psychiatry Rep; 1999 Oct; 1(1):20-4. PubMed ID: 11122901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How does studying schizotypal personality disorder inform us about the prodrome of schizophrenia?
    Seeber K; Cadenhead KS
    Curr Psychiatry Rep; 2005 Mar; 7(1):41-50. PubMed ID: 15717986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.